🏛️ Verified NIH Record • Updated 2026-07-07
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers (NCT05873686)
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Nuvectis Pharma, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (29 items).
Location: Mayo Clinic — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies.
- Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
- Ongoing toxic manifestations of previous treatments \> Grade 2 with the exception of alopecia and neuropathy.
- Subjects with treated brain metastases with evidence of progression within 28 days after central nervous system (CNS)-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\] scan) during the Screening period.
- Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of contraception .
- Male subjects with partners of childbearing potential, unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).
- Major surgery from which the subject has not yet recovered. Part B: Inclusion Criteria:
- Provide written informed consent.
- 18 years old or older.
- Advanced, metastatic, and/or progressive solid tumors with pathogenic molecular alterations:
- Non-small cell lung cancer (adenocarcinoma); YES1, TYMS amplification or FAT1 pathogenic mutation
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (15 Sites)
- Mayo Clinic — Phoenix, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Mayo Clinic — Jacksonville, Florida
- University of Chicago — Chicago, Illinois
- Mayo Clinic Rochester — Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center — New York, New York
- Cleveland Clinic — Cleveland, Ohio
- Oregon Health and Science University — Portland, Oregon
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology Houston — Houston, Texas
- NEXT Oncology Dallas — Irving, Texas
- NEXT Oncology Virginia — Fairfax, Virginia
- Western General Hospital - NHS Lothian — Edinburgh,
- The Royal Marsden NHS Foundation and Trust — London,
📞 Contact the Study Coordinator
Phone: (201) 627-8129
Email: ebelshaw@nuvectis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors — San Antonio, Texas
- Study in Advanced Solid Tumor Patients — Boston, Massachusetts
- Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors — La Jolla, California
- JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors — Encinitas, California
- A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors — Los Angeles, California
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.